How to raise interest in medicines development: Results from Workgroup 1

•

0 likes•2,059 views

The document reports on a workshop discussing strategies to raise public interest in medicines development. Participants were divided into tables to brainstorm potential messaging approaches. The top four issues agreed upon were: 1) knowledge of one's health leads to wellness, 2) people care about food ingredients so they should care about medicine ingredients, 3) patients are essential to medical research, and 4) people can learn about drugs from the independent EUPATI website. Some discussion followed on how to frame each message.

Health & Medicine

EUPATI 2014 Workshop, 2 April 2014, Warsaw
Your input to the EUPATI General Public Information Strategy
Report from Working Group 1
How to raise interest in medicines development?
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n 115334, resources of which are composed
of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.

Many issues:
 7 tables, 6-8 people/table
 12 points per table
 From these 4 taken
 Majority agreed on the next 4 issues
 Some tables were discussing on how rather than
what should be messaged

Top 4 issues
 * my knowledge = my wellness/wellbeing/health
 * you care about your food: are you curious about
what goes into your medicine?
 * without you there is no research
 * know your drugs: visit EUPATI for reliable,
independent info

Top 4 issues
 * my knowledge = my wellness/wellbeing/health
or: our knowledge = our wellness/…)
 Across diseases, so message to all

Top 4 issues
 * you care about your food: are you curious about
what goes into your medicine?
 Message to everyone, mainly adults.
 However, timing crucial (when to be advertised?)

Top 4 issues
 * without you there is no research
 Can it be understood by every patient?
 Via patient organisations or public space.

Top 4 issues
 * know your drugs: visit EUPATI for reliable,
independent info
 Not really seen as message, but rather
advertisement for EUPATI. No solution.

Extra points
 * people want EUPATI not to be separate
=> feeling of inclusion
* no talking about safety of drugs (in contrast to
EU survey) participants see it from the positive
side

The document summarizes findings from a large survey and qualitative research exploring public knowledge and attitudes towards medicines research and development (R&D) in six European countries. Key findings include: - Low overall knowledge about medicines R&D across countries, ranging from 13-30% knowledgeable. - Varied levels of trust in different R&D stakeholders between countries. - Greatest interest in learning more about medicines safety, personalized medicine, and drug discovery. - Preferred sources of information are doctors, websites, and television. - Suggested focus areas for public engagement include the R&D process, clinical trials, regulations, and patient roles.

FASS - Presentation and discussion of Good Practice Example: Maliniak

Nowgen

Rare Disease Day: Discussion of a good practice example: Mavris

Nowgen

G1 report from breakout group 1

EUPATI

This document summarizes the discussion from Break-Out Group 1 at the EUPATI 2015 Workshop regarding implementing EUPATI at the national level. Some key benefits of establishing a national EUPATI partner (ENP) include having a central point of contact for health policy questions, connecting diverse stakeholders, and facilitating multi-sectoral cooperation. National partners could include patient organizations, academics, regulatory authorities, healthcare professionals, and pharmaceutical companies. Strategic priorities for ENPs include disseminating EUPATI training and strengthening partnerships. Success would involve raising awareness, securing institutional support and sustainable funding, and becoming a go-to resource. ENPs should focus on building relationships, learning from more established programs, and leveraging partnerships

Communication & social media

EUPATI

This document provides guidance on using social media and communication tools effectively for patient organizations. It discusses how to create an online voice, examples from successful patient ambassadors, lessons from their experiences, and techniques for working smart with limited resources. Specific strategies and examples are provided for creating a meaningful brand difference, positioning an organization, running typical awareness and advocacy campaigns, and leveraging tools like social media, websites, videos, and crowdfunding campaigns.

The European Patients' Academy (EUPATI) project aims to educate patients and the public about medical research and development. It provides training to help patients become experts who can actively partner with researchers. The project is led by patients and involves various stakeholders. It has made progress in developing educational materials in multiple languages and establishing national networks. The first training course for patient experts recently began. EUPATI seeks to build understanding and empower patients to more actively engage in research.

EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...

EUPATI

EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...

EUPATI

This document discusses increasing patient involvement in medical research and development. It notes that the medical landscape is transforming rapidly through innovations like personalized medicine and biomarkers. While this benefits patients, it also means smaller trial populations and a need for more post-marketing data. The document advocates for increasing patient involvement in areas like clinical trial design, setting research priorities, measuring quality of life, and pharmaceutical policy. It highlights the European Patients' Academy (EUPATI) project, which aims to empower patients through education on medical research and development processes in order to facilitate greater patient engagement.

EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...

EUPATI

G2 report from breakout group 2

EUPATI

The document discusses setting up a National Learning Team (NLT) to establish a European Patients' Academy (ENP) in their country to implement the EUPATI program before the end of 2015. Key points discussed include finding champions in patient organizations, academia, and industry; creating effective partnerships between these stakeholders; developing strategic links and growing networks; and emphasizing the benefits EUPATI can provide like training opportunities and access to resources to promote patient public involvement.

G4 report from breakout group 4

EUPATI

The document summarizes discussions from a breakout group at the EUPATI 2015 Workshop regarding keeping EUPATI initiatives going over the long term and ensuring their success. Key points discussed include: - Sharing best practices and experiences between national EUPATI initiatives to promote sustainability. - Engaging local stakeholders through formal structures, promotional materials, transparency, and varied communication strategies. - Positioning national initiatives as credible sources of information and links to European decision-making. - Expanding collaboration between stakeholders and developing patient leadership over time.

EUPATI patient expert training course and its relevance for patient involvement

EUPATI

The document discusses the EUPATI Patient Expert Training Course. It aims to educate and empower patients to be actively involved in all stages of medicine research and development from drug discovery through regulatory approval. The course includes 150-175 hours of online learning over 6 modules, along with two in-person meetings. It covers topics like clinical trials, ethics, regulations, health technology assessments, and more. The goal is to train independent and knowledgeable patient advocates who can partner with academics, industry, and regulators. Over 300 patients applied for the first class of 50-50 trainees, showing high interest. The course materials were developed by experts from different stakeholders and underwent extensive review.

Introduction to the breakout sessions & case studies presentations

EUPATI

This document discusses Romania's progress toward establishing a national EUPATI platform. It notes that patients are currently represented in law debates regarding the health system and hospital ethics committees, but not in committees for the Romanian Drug Agency or health technology assessment meetings. It then outlines the initial steps taken to form a national EUPATI liaison team, including identifying trainees, academic representatives, media partners, and representatives from healthcare professional bodies. The document concludes by describing how EUPATI can benefit patients and advocates in Romania by increasing health literacy and facilitating greater participation in clinical trials and health policy decisions.

G3 report from breakout group 3

EUPATI

This document summarizes a breakout group discussion from a EUPATI workshop on implementing the EUPATI project in countries where it is not already established. The group discussed how interested supporters in non-EUPATI countries could still work to establish EUPATI principles nationally by: looking for drivers and goals; requesting support materials from EUPATI; addressing potential hurdles; learning from other countries' experiences; and planning for sustainability without EUPATI funding. The breakout group represented 17 countries and identified steps individuals could take to advance patient involvement in medicines R&D where no formal EUPATI National Platform currently exists.

European Patients Academy - Presentation of Jan Geissler at EPF AGM

jangeissler

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...

EUPATI

Introduction to the break out sessions & case studies presentations

EUPATI

The document summarizes the status of EUPATI in Spain. It outlines that a Spanish National Team was established in 2013 with various partners. Key accomplishments include launching the Spanish ENP, holding informational events, and establishing an Executive Board with representatives from patient organizations, academia, and pharmaceutical companies. Current activities involve spreading awareness and developing an action plan. Looking ahead, the Spanish team aims to have more participants in EUPATI training courses, utilize upcoming educational tools, and support new regulations enabling greater patient involvement in research and policy.

Derick mitchell, IPPOSI

Investnet

This document summarizes an organization called IPPOSI that trains patient experts on clinical research, health technology assessment, and eHealth. It discusses IPPOSI's members from science and industry backgrounds. It also describes EUPATI, a project that develops patient education on medicines research and development. EUPATI has trained over 100 patient experts and created educational materials available to over 12,000 patient advocates and 100,000 members of the public interested in health topics. The goal is to facilitate greater patient involvement in research by building competencies among patients.

Future Health Summit - Dr Derick Mitchell - May 26th 2016

ipposi

This document discusses patient involvement in health research. It describes how patients can play key roles across various aspects of research including as public advisors, reviewers, co-researchers, and driving forces. It also outlines training programs for patients, such as those developed by IPPOSI and EUPATI, and how patients can be educated on clinical research, health technology assessment, and other areas. The goal is for patients to have objective knowledge about medical research and development processes to facilitate greater collaboration between patients and researchers.

PPI Conference Galway - Dr Derick Mitchell - April 27th 2016

ipposi

This document discusses the role of patients in science, industry, and research. It describes IPPOSI, a public-private partnership between patients, science, and industry in Ireland. IPPOSI members include patient advocacy groups and conduct various patient-led activities. The document also discusses EUPATI, a project to educate patients and the public about medicines research and development through training courses and an online toolbox. EUPATI aims to facilitate greater patient involvement in clinical research and regulatory processes.

EUPATI Launch Meeting - Jan Geissler

jangeissler

The document summarizes the European Patients' Academy on Therapeutic Innovation (EUPATI) project. EUPATI aims to (1) develop and disseminate education on medicines research and development to patients and the public, (2) build competency among patient advocates, and (3) create a public library on patient information. By empowering patients, EUPATI seeks to facilitate greater patient involvement in research and development to support various stakeholders. Running from 2012 to 2017, EUPATI's consortium of 29 members is funded by the Innovative Medicines Initiative to develop objective and credible educational resources.

EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015

jangeissler

Good practices in patient involvement in HTA

EUPATI

Patients and caregivers have unique knowledge and perspectives about living with an illness that can help inform health technology assessments (HTA). Their involvement is recommended at every stage of the HTA process, from topic selection to disseminating results. However, challenges exist in ensuring patient views are representative and not biased. Different countries in Europe are implementing patient involvement in HTA to varying degrees, with some holding training programs and allowing patient groups to initiate research or contribute to appraisals. Ongoing efforts are needed to strengthen patient involvement through resources, training, and embedding it in all new HTA processes.

Workshop 7 - "Presentation of the International Federation for Spina Bifida a...

EURORDIS - Rare Diseases Europe

Workshop 6 - "Feedback from the 15 National Conferences"

EURORDIS - Rare Diseases Europe

Ev 20141028 c03_en

Georgi Daskalov

1. The document discusses the EU Programme for Action on Global Health and its focus on strengthening health systems and developing sustainable health workforces worldwide using a rights-based approach. 2. It describes several EU-funded projects that aim to increase knowledge about human resources for health, promote policy coherence for development, and call on European decision-makers to ensure sustainable health systems globally. 3. The Ebola outbreak is presented as exposing the consequences of weak health systems and workforce shortages, and a wake-up call for long-term investments in public health capacities including community health workers.

2014 01 21 minutes parents meeting (1)

pagim

The document contains minutes from a parents' organization meeting held from February 14-16, 2014 in Freising, Germany. Key topics discussed included using consistent branding to promote causes like World Prematurity Day, the importance of social media for non-profits, fundraising strategies, developing European standards of care for newborns, and providing feedback on the draft Every Newborn Action Plan. Participants agreed to promote WPD in 2014 through activities like lighting buildings purple and sharing sock images, and to endorse the project to establish harmonized newborn health standards in Europe.

What's hot

Introduction to the workshop and EUPATI update

EUPATI

EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...

EUPATI

EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...

EUPATI

EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...

EUPATI

G2 report from breakout group 2

EUPATI

G4 report from breakout group 4

EUPATI

EUPATI patient expert training course and its relevance for patient involvement

EUPATI

Introduction to the breakout sessions & case studies presentations

EUPATI

G3 report from breakout group 3

EUPATI

European Patients Academy - Presentation of Jan Geissler at EPF AGM

jangeissler

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...

EUPATI

Introduction to the break out sessions & case studies presentations

EUPATI

Derick mitchell, IPPOSI

Investnet

Future Health Summit - Dr Derick Mitchell - May 26th 2016

ipposi

PPI Conference Galway - Dr Derick Mitchell - April 27th 2016

ipposi

EUPATI Launch Meeting - Jan Geissler

jangeissler

EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015

jangeissler

Good practices in patient involvement in HTA

EUPATI

Workshop 7 - "Presentation of the International Federation for Spina Bifida a...

EURORDIS - Rare Diseases Europe

Workshop 6 - "Feedback from the 15 National Conferences"

EURORDIS - Rare Diseases Europe

What's hot (20)

Introduction to the workshop and EUPATI update

EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...

EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...

EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...

G2 report from breakout group 2

G4 report from breakout group 4

EUPATI patient expert training course and its relevance for patient involvement

Introduction to the breakout sessions & case studies presentations

G3 report from breakout group 3

European Patients Academy - Presentation of Jan Geissler at EPF AGM

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...

Introduction to the break out sessions & case studies presentations

Derick mitchell, IPPOSI

Future Health Summit - Dr Derick Mitchell - May 26th 2016

PPI Conference Galway - Dr Derick Mitchell - April 27th 2016

EUPATI Launch Meeting - Jan Geissler

EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015

Good practices in patient involvement in HTA

Workshop 7 - "Presentation of the International Federation for Spina Bifida a...

Workshop 6 - "Feedback from the 15 National Conferences"

Similar to How to raise interest in medicines development: Results from Workgroup 1

Ev 20141028 c03_en

Georgi Daskalov

2014 01 21 minutes parents meeting (1)

pagim

Natural Gas Health Effects Survey - Wheeling, WV

Marcellus Drilling News

A survey being sponsored by the Wheeling-Ohio County Health Department that supposedly will determine if natural gas drilling in that part of WV is having an impact on so-called public health. The survey asks questions about common ailments suffered by everyone at one time or another, and then will compare the results to see if people living near drilling have an increase in those symptoms. The fatal problem with the survey is that it's completely self-reported. People lie and will do so on this survey. Therefore, the results will be null and void.

Pedro Oliveira - Patient Innovation: When Patients Set Out to Help Themselves...

Crowdsourcing Week

Prostate cancer nov 11, 2015

ipposi

This document summarizes a presentation about patient involvement in research. It discusses: 1) IPPOSI, an organization that brings together patient groups, industry, and science to expedite development of innovative therapies and influence related policy in Ireland. 2) Current levels of clinical trial activity and the Irish public's attitudes toward clinical research, which show limited understanding but willingness to participate. 3) The need for more patient and researcher training to build understanding and partnership. The EUPATI program provides such training to develop "patient experts" who can meaningfully contribute to research. 4) Ireland's national platform involves several patient organizations to disseminate EUPATI training and build expertise among patients and advocates.

Research managers jan 14th, 2016 - ipposi presentation

ipposi

What we’ve learned working with health journalists across Europe by John Lister

EvidenceNetwork.ca

Finding and using of health information

Accra School of Hygiene

If you are gathering information on a local area for the first time, it would be helpful to share the work, and the findings, with colleagues. Working with colleagues needs to be done in conjunction with establishing links with local people. Gathering and updating all these different kinds of information is an ongoing project for every health promoter. There are a number of different kinds of information you can access when identifying need.

Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013

EUPATI

Hilary evans editted version

alzscotslides

Global research into Alzheimer's and dementia is needed to address the growing global crisis of these diseases. Alzheimer's Research UK works to increase awareness of dementia as brain diseases, fund scientific research around the world, and translate scientific findings into new treatments through partnerships like the Dementia Consortium and Drug Discovery Alliance. The UK government has also made a Challenge on Dementia 2020 to accelerate progress toward prevention, diagnosis, research and care.

Tom Deblanco: maximising patient engagement

Nuffield Trust

(1) A study gave patients access to their doctors' visit notes through online portals to examine the impact of "open notes". (2) Over 80% of patients read their notes, reporting benefits like better care, understanding, and control of their health. (3) Doctors were initially concerned about increased workload but saw little real impact. (4) After one year, both patients and doctors overwhelmingly wanted to continue open notes access.

Sustainable Health Financing through Health Promotion Funds by Dr. Ulysses Do...

HealthJustice Philippines

The document discusses options for spending 1 billion pesos annually to improve population health in the Philippines. It argues that the best option is to invest in health promotion programs rather than just giving money to individuals or keeping it. Health promotion focuses on strengthening health resources for all people by changing environments and behaviors. It has the highest return on investment compared to disease management and prevention. The document outlines best practices for setting up a sustainable health promotion fund, including securing long-term funding through a surcharge tax and independent governance. It examines opportunities to improve health promotion in the Philippines through universal coverage, health promotion legislation, and allocating revenues from sin taxes.

The Mental Health Europe Bucharest Manifesto “Beyond the bio-medical paradigm...

Raffaele Barone

The Mental Health Europe Bucharest Manifesto calls for alternatives to the dominant biomedical model of psychiatry. It established a task force to investigate DSM-5 and develop the manifesto, which calls on organizations to take 8 actions, including ensuring users are involved in revisions to diagnostic systems and prioritizing research on positive mental health approaches. The task force is currently focused on monitoring DSM-5 and ICD-11, advocating for "sunshine laws" on pharmaceutical payments, and disseminating alternative practices.

Jan Mos RIVM 22-4-2010

guest04af48

The document discusses the role of the National Institute for Public Health and the Environment (RIVM) in the Netherlands. It notes that RIVM aims to improve public health and safeguard a healthy environment through research, policy support, coordination, and effective communication. While public health decisions require complex tradeoffs, RIVM maintains a scientific and non-partisan role to provide independent and evidence-based recommendations. The document also examines current public health issues and opportunities to promote health and prevention.

Jan Mos Rivm 22 4 2010

ljswever

The document discusses the role of the National Institute for Public Health and the Environment (RIVM) in the Netherlands. It notes that RIVM aims to improve public health and safeguard a healthy environment through research, policy support, coordination, and effective communication. Key responsibilities of RIVM include providing scientific expertise and advice while remaining non-partisan. The document also examines public health issues and challenges facing RIVM, such as increasing chronic diseases, health inequalities, and opportunities for prevention.

CHESS Connected Health training network - Derick Mitchell - August 2016

ipposi

Patient-led organizations can play an important role in health research by providing the patient perspective. Training programs help develop "expert patients" who understand the research process and can actively partner with researchers. The EUPATI program has trained over 100 patient experts across Europe to collaborate in academic research, industry research, and regulatory committees. Their involvement aims to make research more relevant to patients' real needs and lives.

Teresa alves - selling sickness 2010

Gezonde scepsis

The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.

Comparative health care

Study Stuff

This document provides information about getting fully solved assignments by emailing or calling the provided contact details. It then provides a sample comparative healthcare assignment with 7 questions covering topics like healthcare delivery systems in India, initiatives to achieve universal healthcare, India's national health policy and goals, the WHO, UNICEF, health problems in developing nations, national disease control programs, and the US healthcare system structure and functions. Answers are provided for some of the questions as examples.

United Nations Millennium Development Goals

Jessica McAllister

EUPATI – EU: An overview (Eibhlin Mulroe, EUPATI / IPPOSI)

Nowgen

Similar to How to raise interest in medicines development: Results from Workgroup 1 (20)

Ev 20141028 c03_en

2014 01 21 minutes parents meeting (1)

Natural Gas Health Effects Survey - Wheeling, WV

Pedro Oliveira - Patient Innovation: When Patients Set Out to Help Themselves...

Prostate cancer nov 11, 2015

Research managers jan 14th, 2016 - ipposi presentation

What we’ve learned working with health journalists across Europe by John Lister

Finding and using of health information

Webinar: EUPATI Update to participants of the EUPATI Focus Groups - 4 Nov 2013

Hilary evans editted version

Tom Deblanco: maximising patient engagement

Sustainable Health Financing through Health Promotion Funds by Dr. Ulysses Do...

The Mental Health Europe Bucharest Manifesto “Beyond the bio-medical paradigm...

Jan Mos RIVM 22-4-2010

Jan Mos Rivm 22 4 2010

CHESS Connected Health training network - Derick Mitchell - August 2016

Teresa alves - selling sickness 2010

Comparative health care

United Nations Millennium Development Goals

EUPATI – EU: An overview (Eibhlin Mulroe, EUPATI / IPPOSI)

More from Nowgen

Involvepresentation

Nowgen

The document discusses patient involvement in pharmaceutical research and development. It describes the European Patients' Academy project, which aims to build patient and public competencies and facilitate their involvement in research. The findings of a qualitative study on pharmaceutical industry professionals' beliefs are presented. While most believed patients should be involved, there were few concrete plans and uncertainty around how to operationalize involvement. Challenges included patients' research knowledge and distrust of industry. Facilitators included increased transparency and revised codes of practice. The discussion focuses on lessons to be learned across public and private research and recommendations for meaningful patient involvement.

Brookman final last 5 nov

Nowgen

This document discusses improving patient involvement in clinical research. It outlines potential advantages of patient involvement including better understanding patient needs, identifying trial hurdles and relevant outcomes, and improving trial protocols and recruitment. Challenges to patient involvement include a lack of experience, unclear rules for collaborating with advocacy groups, and balancing patient wishes with feasibility. The document describes Janssen collaborating with advocacy groups on a prostate cancer trial after they identified recruitment issues. It also discusses overcoming barriers through codes of practice and measuring outcomes of collaboration developed with EUPATI.

Sireau eupati presentation for webinar v2

Nowgen

This document discusses lessons learned from improving patient involvement in clinical research based on studies of Alkaptonuria (AKU), a rare genetic disorder. It outlines the history and metabolic pathway of AKU and efforts by patient groups to fund pre-clinical research. This included developing a cell and mouse model of AKU, identifying the drug Nitisinone which reduces the main toxin in AKU by 95%, and conducting three clinical trials of Nitisinone across sites in the UK, France and Slovakia. The trials demonstrated promise for treating AKU and improving patients' lives. The document concludes by addressing challenges and solutions for greater collaboration between patient groups, industry and academia.

Pavitt ppi impact on clinical research vs1

Nowgen

This document discusses the benefits of patient and public involvement (PPI) in clinical trials. PPI can enhance the relevance of clinical research by ensuring the research questions and design address patient priorities and experiences. Case studies demonstrate how PPI improved informed consent materials, addressed logistical barriers to participation, and increased recruitment and retention. When done effectively, PPI leads to clinical trials that are more meaningful to patients and deliver research that better addresses patient needs.

S brookman may eupati webinar final 5 nov

Nowgen

This document summarizes a webinar on improving patient involvement in clinical research activities. It includes presentations from panelists on the benefits of patient involvement from different perspectives. A professor discusses how patient input improved trial design, logistics, and recruitment in past studies. A patient representative talks about their organization's work with industry to fund research and develop a treatment for a rare disease. A pharmaceutical representative discusses challenges and opportunities for patient collaboration in clinical research and development. The webinar aimed to explore how frameworks and guidelines could better enable patient-industry partnerships in research.

Introduction to the Workshop & Participant Statistics

Nowgen

Involving People: Patients, Participants & Consumers in U.K.Cancer Research (...

Nowgen

Working with young people to shape research – reaping the benefits & the impo...

Nowgen

Patients at the Centre for Health Research – Patient, Carer and Public Invol...

Nowgen

INVOLVE perspectives on learning and development (Sarah Buckland, INVOLVE)

Nowgen

Patient involvement in clinical research and long term conditions -what can b...

Nowgen

Patients at the core of medical research & development (Emma Law, Scottish De...

Nowgen

Bringing the patient voice into GSK for educational, awareness and patient ce...

Nowgen

Patient involvement in medicines development – the views of patients and key ...

Nowgen

More from Nowgen (14)